{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-102834","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.272426+00:00","generated_at":"2026-05-17T01:57:46.368027+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kiniksa Q3 ARCALYST revenue $180.9M (+61% YoY); raises 2025 guidance to $670-675M","bullets":["Net income $18.4M (vs loss $12.7M); cash $352.1M, no debt.","ARCALYST net product revenue $180.9M, up 61% YoY; total revenue $180.9M.","2025 revenue guidance raised to $670-675M from prior $625-640M.","KPL-387 granted Orphan Drug Designation; Phase 2/3 data H2 2026.","Prescribers >3,825; average therapy duration ~32 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-102834","json":"https://secwatch.observer/filing/0001104659-25-102834.json","markdown":"https://secwatch.observer/filing/0001104659-25-102834.md","text":"https://secwatch.observer/filing/0001104659-25-102834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925102834/0001104659-25-102834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465925102834/tm2529531d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:57:46.368027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}